ISRG stock forecast, quote, news & analysis
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery... Show more
Intuitive Surgical (ISRG) Stock Analysis: A Recurring-Revenue Engine Backing a Premium Valuation
Key Takeaways
- ISRG shares traded near $393 in mid-September, up roughly 3.8% from a month earlier, keeping the stock within a moderate range rather than a sharp directional move.
- Second-quarter 2026 revenue rose 19% year over year to $2.89 billion, with recurring revenue of $2.47 billion representing 85% of total sales.
- Management maintained full-year 2026 da Vinci procedure growth guidance of 13.5% to 15.5% and raised its non-GAAP gross margin outlook to 68% to 69%.
- The business follows a "razor-and-blade" model, where instruments, accessories, and services tied to a large installed base drive predictable, high-margin revenue.
- Key watch items include moderating U.S. procedure growth, GLP-1 pressure on bariatric cases, and competitive and pricing dynamics in China.
Current Market Snapshot
Intuitive Surgical (ISRG) has traded in a wide but contained band over the trailing month. After climbing toward roughly $401 in mid-August, the stock pulled back to the low-$350 area in early September before rebounding to about $393, leaving shares modestly higher versus a month earlier. This choppiness reflects a market weighing durable demand for robotic-assisted surgery against signs of slower U.S. procedure growth in deferrable categories and ongoing caution around international markets.
Within the medical technology sector, Intuitive continues to command a premium valuation relative to many peers, supported by its dominant installed base, high-margin recurring revenue, and long runway for penetration of minimally invasive procedures. Investor sentiment has been broadly constructive but increasingly focused on utilization trends and pricing rather than headline system placements alone.
Intuitive Surgical (ISRG) Business Overview and Competitive Position
Headquartered in Sunnyvale, California, Intuitive Surgical is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. The company's core technologies are the da Vinci surgical systems and the Ion endoluminal system, the latter aimed primarily at lung biopsy and diagnosis. These platforms are complemented by proprietary instruments, accessories, training, and multi-year service contracts.
Intuitive operates on a "razor-and-blade" model. System placements generate an initial sale, but the economics are anchored by recurring revenue from instruments, accessories, leases, and services that rise with utilization and installed-base growth. In the second quarter of 2026, recurring revenue accounted for 85% of total sales, and the company ended the period with nearly 13,000 systems installed worldwide. High switching costs, surgeon familiarity, and a deep clinical evidence base create a substantial competitive moat that has historically been difficult for rivals to displace.
Recent Developments Driving ISRG
Intuitive's second-quarter 2026 results, reported in July, reinforced the durability of its model. Total procedures grew 16% year over year, including 15% growth in da Vinci procedures and 36% growth in Ion procedures. Revenue climbed 19% to $2.89 billion, while non-GAAP earnings per share increased 28% to $2.80. Results included a $36 million pre-tax benefit tied to a refund of previously paid IEEPA tariffs.
Demand for the newer da Vinci 5 platform remained a central catalyst, with placements driving an upgrade cycle that lifts average selling prices and utilization. Management noted that da Vinci 5 has been adopted by more than 15,000 surgeons since launch. At the same time, Ion procedure volumes continued to scale rapidly, and the company highlighted progress on digital offerings such as the My Intuitive+ subscription as an emerging software-led revenue layer.
Offsetting these strengths, U.S. da Vinci procedure growth moderated to 12% in the quarter, with management citing customer feedback around insurance coverage and premium changes as well as pressure on bariatric procedures from rising GLP-1 usage. International procedure growth of 20% helped balance softer domestic trends, though China remained challenged by competitive and pricing dynamics.
Trending AI Robots
For traders seeking a systematic approach to the market, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron provides hundreds of AI-driven bots that trade thousands of tickers, but only the most relevant and best-performing strategies appear in this featured section. These bots vary widely in strategy, timeframe, and performance metrics, giving users a way to compare different automated approaches side by side. Whether you are interested in short-term signals or longer-horizon strategies, the page is designed to help you identify tools aligned with your own trading objectives. Explore the section to see which AI robots are currently leading the field.
2026 Outlook and What Investors Should Watch
Looking ahead, the central question for Intuitive is whether global procedure growth can sustain its mid-teens pace as the U.S. market matures. Investors should monitor the trajectory of da Vinci 5 upgrades and whether higher utilization on the new platform translates into stronger instrument and accessory pull-through. Ion's expansion and the rollout of digital subscriptions represent additional levers that could diversify revenue beyond hardware and procedure volume.
On the risk side, watch items include further moderation in U.S. deferrable procedures, the ongoing effect of GLP-1 therapies on bariatric volumes, tariff exposure, hospital capital budgets, and competitive and pricing pressure in China and other value-sensitive markets. Management's updated gross margin outlook and any changes to procedure guidance on upcoming earnings calls will be closely scrutinized. As always, these factors should be weighed against the company's premium valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ISRG in upward trend: 10-day moving average crossed above 50-day moving average on September 21, 2026
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on ISRG as a result. In 57 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ISRG just turned positive on September 14, 2026. Looking at past instances where ISRG's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
ISRG moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 213 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
ISRG broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ISRG entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ISRG’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.645) is normal, around the industry mean (4.961). P/E Ratio (45.107) is within average values for comparable stocks, (161.442). Projected Growth (PEG Ratio) (1.831) is also within normal values, averaging (4.443). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther